MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturities
of marketable...
$46,142K
Proceeds from issuances
of common stock...
$2,219K
Proceeds from issuances
of common stock...
$468K
Proceeds from exercise of
stock options
$9K
Net cash provided by
investing activities
$23,985K
Net cash provided by
financing activities
$2,696K
Canceled cashflow
$22,157K
Net (decrease)
increase in cash, cash...
-$303K
Canceled cashflow
$26,681K
Stock-based compensation
expense
$2,357K
Depreciation and
amortization
$649K
Prepaid expenses and
other current assets
-$522K
Other receivables
-$459K
Contract assets
-$315K
Non-cash lease expense
$315K
Other assets
-$63K
Purchases of marketable
securities
$22,085K
Purchases of property and
equipment
$72K
Net cash used in
operating activities
-$26,984K
Canceled cashflow
$4,680K
Licensing and other
third-party revenue
$2,397K
Other income, net
$1,195K
Net loss
-$25,085K
Accrued expenses and
other current...
-$2,646K
Canceled cashflow
$3,592K
Accounts payable
-$2,220K
Deferred revenue,
current and long-term
-$1,005K
Operating lease
liabilities
-$281K
Accretion of discounts on
investments in marketable...
$269K
Accounts receivable
$158K
Total research and
development
$18,869K
General and
administrative
$6,802K
Other segment items
$3,006K
External costs
$10,690K
Internal costs
$8,179K
Back
Back
Cash Flow
Caribou Biosciences, Inc. (CRBU)
Caribou Biosciences, Inc. (CRBU)
source: myfinsight.com